Steven G DuBois Selected Research

3-Iodobenzylguanidine (Iobenguane)

1/2022	Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma.
11/2021	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
11/2017	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
11/2017	Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma.
10/2016	Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
7/2016	Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
3/2016	Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
3/2016	Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma.
3/2016	Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
6/2015	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven G DuBois Research Topics

Disease

79	Neoplasms (Cancer) 08/2022 - 06/2004
38	Neuroblastoma 01/2022 - 06/2004
17	Ewing Sarcoma (Sarcoma, Ewing) 12/2021 - 03/2009
11	Sarcoma (Soft Tissue Sarcoma) 08/2022 - 03/2015
8	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 03/2009
5	Carcinoma (Carcinomatosis) 01/2022 - 01/2018
4	Neoplasm Metastasis (Metastasis) 11/2017 - 05/2009
4	Thrombocytopenia (Thrombopenia) 05/2017 - 06/2004
3	Fibrosarcoma 08/2022 - 01/2018
3	Disease Progression 01/2022 - 11/2018
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2021 - 01/2020
3	Nausea 01/2020 - 01/2018
3	Fatigue 01/2020 - 12/2016
3	Neutropenia 10/2017 - 06/2004
2	Central Nervous System Neoplasms 01/2022 - 01/2021
2	Rhabdomyosarcoma 01/2021 - 03/2015
2	Infections 01/2021 - 10/2014
2	Lymphoma (Lymphomas) 01/2020 - 08/2016
2	Residual Neoplasm 01/2020 - 12/2016
2	Vomiting 01/2020 - 01/2018
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2017 - 10/2014
2	Chromosome Aberrations (Chromosome Abnormalities) 03/2016 - 10/2014
2	Wilms Tumor (Wilm's Tumor) 10/2012 - 07/2012
1	Soft Tissue Neoplasms 08/2022
1	Ganglioneuroblastoma 01/2022
1	Glomus Tumor (Glomus Tumors) 01/2022
1	Sudden Death 01/2022
1	Polycythemia (Erythrocytosis) 11/2021
1	Hypertension (High Blood Pressure) 11/2021
1	Hypoxia (Hypoxemia) 11/2021
1	Paraganglioma (Paragangliomas) 11/2021
1	Headache (Headaches) 11/2021
1	Pinealoma (Pineoblastoma) 01/2021
1	Adenocarcinoma 01/2021
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2021

Drug/Important Bio-Agent (IBA)

15	3-Iodobenzylguanidine (Iobenguane)IBA 01/2022 - 08/2008
12	Pharmaceutical PreparationsIBA 01/2022 - 01/2019
10	Biological ProductsIBA 01/2022 - 11/2011
10	Proteins (Proteins, Gene)FDA Link 11/2021 - 03/2009
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2015
7	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 07/2012
6	larotrectinibIBA 01/2022 - 01/2018
6	Irinotecan (Camptosar)FDA LinkGeneric 11/2021 - 05/2012
5	Phosphotransferases (Kinase)IBA 08/2022 - 01/2018
5	Vincristine (Oncovin)FDA LinkGeneric 12/2021 - 05/2012
5	Sunitinib (Sutent)FDA Link 05/2021 - 04/2012
5	RadiopharmaceuticalsIBA 03/2016 - 05/2012
4	RNA (Ribonucleic Acid)IBA 01/2022 - 04/2017
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 05/2009
4	Vorinostat FDA Link 11/2021 - 07/2011
4	Radiation-Sensitizing AgentsIBA 01/2018 - 07/2011
3	TropomyosinIBA 01/2022 - 01/2018
3	Alanine Transaminase (SGPT)IBA 01/2021 - 12/2016
3	Nuclear Proteins (Protein, Nuclear)IBA 01/2021 - 04/2020
3	Temozolomide (Temodar)FDA LinkGeneric 10/2020 - 04/2016
3	Circulating Tumor DNAIBA 04/2020 - 01/2018
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020 - 12/2016
3	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 11/2017 - 08/2008
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2022 - 04/2020
2	Topotecan (Hycamtin)FDA LinkGeneric 12/2021 - 04/2017
2	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 05/2013
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 03/2019
2	Busulfan (Busulfex)FDA Link 01/2021 - 05/2013
2	MLN 8237IBA 12/2018 - 04/2016
2	Etoposide (VP 16)FDA LinkGeneric 05/2017 - 05/2009
2	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 07/2016 - 03/2016
2	Ferritins (Ferritin)IBA 03/2016 - 10/2014
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 03/2016 - 10/2014
2	Radioisotopes (Radionuclides)IBA 01/2016 - 04/2015
2	Insulin (Novolin)FDA Link 01/2016 - 03/2015
1	tyrosine receptor (receptor, tyrosine)IBA 08/2022
1	ran-binding protein 2IBA 08/2022
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 08/2022
1	dinutuximabIBA 01/2022
1	Oncogene Proteins (Oncogene Protein)IBA 01/2022
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022
1	CytokinesIBA 01/2022
1	Iodine-131IBA 01/2022
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2022
1	morinIBA 11/2021
1	belzutifanIBA 11/2021
1	CrizotinibIBA 11/2021
1	Anaplastic Lymphoma KinaseIBA 11/2021
1	Investigational DrugsIBA 04/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Genetic Markers (Genetic Marker)IBA 01/2021
1	olaratumabIBA 01/2021
1	NucleotidesIBA 01/2021
1	TransferasesIBA 01/2021

Therapy/Procedure

45	Therapeutics 08/2022 - 06/2004
18	Drug Therapy (Chemotherapy) 12/2021 - 03/2009
10	Radiotherapy 01/2022 - 08/2008
4	Stem Cell Transplantation 01/2021 - 05/2013
4	Induction Chemotherapy 01/2021 - 07/2014
2	Investigational Therapies (Experimental Therapy) 04/2021 - 01/2020
2	Precision Medicine 01/2021 - 05/2016
2	Aftercare (After-Treatment) 11/2018 - 10/2016
1	Salvage Therapy 01/2022
1	Immunotherapy 01/2022
1	Combined Modality Therapy 10/2020